{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:59:55Z","timestamp":1787021995051,"version":"build-2736575974"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0170663","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T13:39:13Z","timestamp":1485869953000},"page":"e0170663","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania"],"prefix":"10.1371","volume":"12","author":[{"given":"Andrew","family":"Ebers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Stroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellah","family":"Mpagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riziki","family":"Kisonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaack","family":"Lekule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"issue":"9728","key":"ref1","first-page":"1830","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"NR Gandhi","year":"2010"},{"key":"ref2","first-page":"153","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"EW Orenstein","year":"2009"},{"key":"ref3","first-page":"1464","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"JG Pasipanodya","year":"2013"},{"issue":"5","key":"ref4","first-page":"e62034","article-title":"Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania","volume":"8","author":"SG Mpagama","year":"2013"},{"issue":"2","key":"ref5","first-page":"782","article-title":"Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis","volume":"58","author":"SG Mpagama","year":"2014"},{"issue":"3","key":"ref6","first-page":"e0122769","article-title":"Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis","volume":"10","author":"ND Ndusilo","year":"2015"},{"issue":"7","key":"ref7","first-page":"3800","article-title":"Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis","volume":"59","author":"A Alsultan","year":"2015"},{"key":"ref8","first-page":"839","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"A Alsultan","year":"2014"},{"issue":"2","key":"ref9","first-page":"e02273","article-title":"Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes","volume":"6","author":"S Pholwat","year":"2015"},{"issue":"11","key":"ref10","first-page":"7104","article-title":"Sensititre MYCOTB MIC plate compared to Bactec MGIT 960 for first and second-line anti-tuberculosis drug susceptibility testing in Tanzania: a call to operationalize minimum inhibitory concentrations","volume":"59","author":"SK Heysell","year":"2015"},{"issue":"10","key":"ref11","first-page":"1546","article-title":"Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA","volume":"16","author":"SK Heysell","year":"2010"},{"issue":"1","key":"ref12","first-page":"83","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis patients","volume":"25","author":"C Magis-Escurra","year":"2012"},{"issue":"4","key":"ref13","first-page":"225","article-title":"Therapeutic drug monitoring in the treatment of active tuberculosis","volume":"18","author":"A Babalik","year":"2011"},{"issue":"5","key":"ref14","first-page":"503","article-title":"Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection","volume":"29","author":"DP Holland","year":"2009"},{"issue":"2","key":"ref15","first-page":"221","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis","volume":"17","author":"L Van Tongeren","year":"2013"},{"issue":"5\u20136","key":"ref16","first-page":"229","article-title":"Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid","volume":"33","author":"J Ray","year":"2003"},{"key":"ref17","first-page":"129723","article-title":"Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA","volume":"2013","author":"SK Heysell","year":"2013"},{"key":"ref18","first-page":"5758","article-title":"Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"56","author":"DH Vu","year":"2012"},{"key":"ref19","first-page":"97","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"JW Alffenaar","year":"2010"},{"key":"ref20","first-page":"1051","article-title":"Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?","volume":"40","author":"K Manika","year":"2012"},{"issue":"6","key":"ref21","first-page":"1770","article-title":"Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients","volume":"126","author":"J Li","year":"2004"},{"issue":"4","key":"ref22","first-page":"961","article-title":"Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB","volume":"56","author":"SH Lee","year":"2015"},{"issue":"9","key":"ref23","first-page":"2066","article-title":"Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS\/MS","volume":"68","author":"M Han","year":"2013","journal-title":"J"},{"key":"ref24","first-page":"247","article-title":"Development and validation of HPLC-UV method for the estimation of levofloxacin in human plasma","volume":"3","author":"TM Kumar","year":"2011"},{"issue":"3","key":"ref25","first-page":"329","article-title":"Sensititre W MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates","volume":"20","author":"X Yu","year":"2016"},{"issue":"3","key":"ref26","first-page":"333","article-title":"Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial","volume":"191","author":"SE Dorman","year":"2015"},{"issue":"8","key":"ref27","first-page":"e1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"SD Ahuja","year":"2012"},{"issue":"10","key":"ref28","first-page":"2841","article-title":"Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study","volume":"69","author":"JB Prahl","year":"2014"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ910","article-title":"Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance","volume":"62","author":"JP Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref30","first-page":"2474","article-title":"Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future","volume":"59","author":"MM Sturkenboom","year":"2015"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0170663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:11:24Z","timestamp":1749924684000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0170663"}},"subtitle":[],"editor":[{"given":"Krystyna","family":"D\u0105browska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0170663","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]}}}